you are here: Home News Eli Lilly

Eli Lilly

Lilly’s first weight loss pill wins US nod, to break access barrier
Eli Lilly to buy Centessa Pharmaceuticals for up to $7.8 billion
Nvidia to invest $1 billion in AI drug laboratory with Eli Lilly
Cipla: Emerging markets to lead growth in the near term
How Eli Lilly’s weight-loss drug Mounjaro gained early lead against Novo Nordisk’s Wegovy in India
Eli Lilly's Mounjaro becomes second-most sold drug in September, posts Rs 80 cr revenue: Report
Eli Lilly to invest over $1 billion in India to expand manufacturing capacity
Roche to buy 89bio for up to $3.5 billion in obesity push
Lilly to launch Mounjaro pen in India to compete with Novo's weight-loss drug Wegovy
CDSCO allows Lilly to launch weight-loss drug Mounjaro in pen format
Eli Lilly may manufacture weight-loss drug Mounjaro in India in future, says CEO David Ricks
Global pharma giants Eli Lilly, Novo Nordisk launch obesity awareness campaigns, exploring India market potential
Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says
Lupin acquires Huminsulin from Eli Lilly to enhance diabetes care portfolio
Divis Lab: GLP-1 opportunity to unfold in the medium term
World Street | Crude oil slumps; Yen drops amid political turmoil; Olympus Corp plunges after CEO drug scandal; and more
World Street | Barnes & Noble founder passes away; Nvidia creates multimillionaires; HBBE rises after ADOR CEO steps down; Bitcoin drops sharply; and more
India panel urges drug regulator to approve Lilly's obesity drug Mounjaro
Alphabet taps Eli Lilly Executive as new CFO replacing Porat
Biocon’s formulations business to outpace API share soon: CEO
Open to market Eli Lilly’s weight loss drugs in India: Cipla CEO
Eli Lilly lifts 2024 revenue guidance by $2 billion on weight-loss pills demand
US FDA delays Lilly Alzheimer's drug decision, calls for advisory panel
Eli Lilly could launch obesity drug in India next year, CEO says
World Street | Maersk takes a long cut; mortgages regain appeal; McDonalds faces pressure

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Eli Lilly

Lilly’s first weight loss pill wins US nod, to break access barrier

Eli Lilly to buy Centessa Pharmaceuticals for up to $7.8 billion

Nvidia to invest $1 billion in AI drug laboratory with Eli Lilly

Cipla: Emerging markets to lead growth in the near term

How Eli Lilly’s weight-loss drug Mounjaro gained early lead against Novo Nordisk’s Wegovy in India

Eli Lilly's Mounjaro becomes second-most sold drug in September, posts Rs 80 cr revenue: Report

Eli Lilly to invest over $1 billion in India to expand manufacturing capacity

Roche to buy 89bio for up to $3.5 billion in obesity push

Lilly to launch Mounjaro pen in India to compete with Novo's weight-loss drug Wegovy

CDSCO allows Lilly to launch weight-loss drug Mounjaro in pen format

Eli Lilly may manufacture weight-loss drug Mounjaro in India in future, says CEO David Ricks

Global pharma giants Eli Lilly, Novo Nordisk launch obesity awareness campaigns, exploring India market potential

Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says

Lupin acquires Huminsulin from Eli Lilly to enhance diabetes care portfolio

Divis Lab: GLP-1 opportunity to unfold in the medium term

World Street | Crude oil slumps; Yen drops amid political turmoil; Olympus Corp plunges after CEO drug scandal; and more

World Street | Barnes & Noble founder passes away; Nvidia creates multimillionaires; HBBE rises after ADOR CEO steps down; Bitcoin drops sharply; and more

India panel urges drug regulator to approve Lilly's obesity drug Mounjaro

Alphabet taps Eli Lilly Executive as new CFO replacing Porat

Biocon’s formulations business to outpace API share soon: CEO

Open to market Eli Lilly’s weight loss drugs in India: Cipla CEO

Eli Lilly lifts 2024 revenue guidance by $2 billion on weight-loss pills demand

US FDA delays Lilly Alzheimer's drug decision, calls for advisory panel

Eli Lilly could launch obesity drug in India next year, CEO says

World Street | Maersk takes a long cut; mortgages regain appeal; McDonalds faces pressure